GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestial Biolabs Ltd (BOM:532871) » Definitions » Capex-to-Revenue

Celestial Biolabs (BOM:532871) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Celestial Biolabs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Celestial Biolabs's Capital Expenditure for the three months ended in Dec. 2023 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was ₹0.37 Mil.

Hence, Celestial Biolabs's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Celestial Biolabs Capex-to-Revenue Historical Data

The historical data trend for Celestial Biolabs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestial Biolabs Capex-to-Revenue Chart

Celestial Biolabs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 - - 0.03 0.04

Celestial Biolabs Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Celestial Biolabs's Capex-to-Revenue

For the Biotechnology subindustry, Celestial Biolabs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celestial Biolabs's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celestial Biolabs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Celestial Biolabs's Capex-to-Revenue falls into.



Celestial Biolabs Capex-to-Revenue Calculation

Celestial Biolabs's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.064) / 1.687
=0.04

Celestial Biolabs's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.368
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celestial Biolabs  (BOM:532871) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Celestial Biolabs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celestial Biolabs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Celestial Biolabs (BOM:532871) Business Description

Traded in Other Exchanges
N/A
Address
Plot No. 59, Road No 12, TSIIC Tech Park, IDA Nacharam, Hyderabad, TG, IND, 500076
Celestial Biolabs Ltd is an India based biopharmaceutical company. It is engaged in the business activity producing and supplying of the biotechnological products. The company offers herbal, feed supplement and nutraceutical products. The proprietary herbal products of the group include BIOVITA, CADALMIN GAE, CEL-DIGEST, BIOLIV, RHUMACEL, CEL-CLEAR, Trem Plus, O-KOF, BIOPOWER GOLD, BIO-DNORM, DERMACEL, GYNOCEL, HEALTHONE, RELIFIN, and C-KAPS. The organization formulates and manufactures Ayurvedic proprietary products for the Indian market.

Celestial Biolabs (BOM:532871) Headlines

No Headlines